interleukin-2: Biology, Design and Application

被引:299
作者
Arenas-Ramirez, Natalia [1 ]
Woytschak, Janine [1 ]
Boyman, Onur [1 ]
机构
[1] Univ Zurich, Dept Immunol, Univ Zurich Hosp, CH-8091 Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
REGULATORY T-CELLS; LOW-DOSE INTERLEUKIN-2; IL-2/ANTI-IL-2 MAB COMPLEXES; INNATE LYMPHOID-CELLS; ACTIVATED B-CELLS; IN-VIVO EXPANSION; MONOCLONAL-ANTIBODY; IMMUNE-COMPLEXES; CUTTING EDGE; RECOMBINANT INTERLEUKIN-2;
D O I
10.1016/j.it.2015.10.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interleukin-2 (IL-2) exerts crucial functions during immune homeostasis via its effects on regulatory T (Treg) cells, and the optimizing and fine-tuning of effector lymphocyte responses. Thus, somewhat paradoxically, low doses of recombinant IL-2 have been used for Treg cell-based immunosuppressive strategies against immune pathologies, while high-dose IL-2 has shown some success in stimulating anti-tumor immune responses. Recent studies of the functional, biophysical and structural characteristics of IL-2 have led to the generation of IL-2 formulations, including IL-2/mAb complexes and IL-2 variants (muteins) that selectively enhance IL-2's immune stimulatory versus inhibitory properties. Here, we review these findings, placing new mechanistic insights into improved next-generation IL-2 formulations within the broader context of IL-2 biology. We conclude by integrating these findings into a framework for understanding IL-2-mediated selective immune modulation.
引用
收藏
页码:763 / 777
页数:15
相关论文
共 87 条
[1]   THE DEVELOPMENT OF ANTI-INTERLEUKIN-2 ANTIBODIES IN PATIENTS TREATED WITH RECOMBINANT HUMAN INTERLEUKIN-2 (IL-2) [J].
ALLEGRETTA, M ;
ATKINS, MB ;
DEMPSEY, RA ;
BRADLEY, EC ;
KONRAD, MW ;
CHILDS, A ;
WOLFE, SN ;
MIER, JW .
JOURNAL OF CLINICAL IMMUNOLOGY, 1986, 6 (06) :481-490
[2]   IL-2 coordinates IL-2-producing and regulatory T cell interplay [J].
Amado, Ines F. ;
Berges, Julien ;
Luther, Rita J. ;
Mailhe, Marie-Pierre ;
Garcia, Sylvie ;
Bandeira, Antonio ;
Weaver, Casey ;
Liston, Adrian ;
Freitas, Antonio A. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 210 (12) :2707-2720
[3]   Cytokine therapy reverses NK cell anergy in MHC-deficient tumors [J].
Ardolino, Michele ;
Azimi, Camillia S. ;
Iannello, Alexandre ;
Trevino, Troy N. ;
Horan, Lucas ;
Zhang, Lily ;
Deng, Weiwen ;
Ring, Aaron M. ;
Fischer, Suzanne ;
Garcia, K. Christopher ;
Raulet, David H. .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (11) :4781-4794
[4]   Binding of small molecules to an adaptive protein-protein interface [J].
Arkin, MR ;
Randal, M ;
DeLano, WL ;
Hyde, J ;
Luong, TN ;
Oslob, JD ;
Raphael, DR ;
Taylor, L ;
Wang, J ;
McDowell, RS ;
Wells, JA ;
Braisted, AC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :1603-1608
[5]   Selective stimulation of T cell subsets with antibody-cytokine immune complexes [J].
Boyman, O ;
Kovar, M ;
Rubinstein, MP ;
Surh, CD ;
Sprent, J .
SCIENCE, 2006, 311 (5769) :1924-1927
[6]   Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease [J].
Boyman, Onur ;
Surh, Charles D. ;
Sprent, Jonathan .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (12) :1323-1331
[7]   Adverse reactions to biologic agents and their medical management [J].
Boyman, Onur ;
Comte, Denis ;
Spertini, Francois .
NATURE REVIEWS RHEUMATOLOGY, 2014, 10 (10) :612-627
[8]   The role of interleukin-2 during homeostasis and activation of the immune system [J].
Boyman, Onur ;
Sprent, Jonathan .
NATURE REVIEWS IMMUNOLOGY, 2012, 12 (03) :180-190
[9]  
Boyman O, 2010, ADV EXP MED BIOL, V684, P28
[10]   Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2 [J].
Carmenate, Tania ;
Pacios, Anabel ;
Enamorado, Michel ;
Moreno, Ernesto ;
Garcia-Martinez, Karina ;
Fuente, Dasha ;
Leon, Kalet .
JOURNAL OF IMMUNOLOGY, 2013, 190 (12) :6230-6238